Abstract 1490P
Background
Tumor necrosis factor (TNF-α) has anticancer activity. Tumors neutralize TNF-α by shedding excess soluble TNF receptors (sTNF-Rs) in the tumor microenvironment preventing TNF-α from binding to tumor membrane bound sTNF-Rs, triggering cell death pathways. Removal of sTNF-Rs via apheresis liberates the anticancer effects of TNF-α alone or with anticancer agents.
Methods
Protocol CP7-008 [NCT04690686] evaluated LW-02 Column Immunopheresis® (‘LW-02 CI’) in advanced (Stages IIIB/IV) squamous or adenocarcinoma NSCLC patients (pts), who progressed 1or 2 line(s) of treatment (1st-line with a platinum salt). Sixteen (16) pts were assigned to 1 of 3 arms to receive LW-02 CI 3x/week: with atezolizumab (Arm 1, n=7), with paclitaxel (Arm 2, n=3) or as monotherapy (Arm 3, n=6; pts progressed 2 lines, or 1 but not suitable for Arm 1) for 16 weeks. Clinically stable and/or objectively improved pts could receive extended therapy.
Results
Safety and tumor burden changes were evaluated in two groups—pts that had at least 1 LW-02 CI treatment (‘ITT’) and pts treated ≥4 weeks (≥4 wks). Pts’ tumor burden was assessed via RECIST 1.1 (or iRECIST if appropriate). After 644 LW-02 CI procedures, 373 AEs (including 22 SAEs) were reported; 18 AEs (14.8%), including 3 SAEs (13.6%), had a causal relationship to treatment with the LW-02 Column. All were Grades 1 or 2, except for 2 Grade 3 SAEs. All resolved, and none required treatment discontinuation. For tumor burden, the best overall response was stable disease (11 pts), durable for ≥8 wks. Other endpoints were duration of treatment (DoT), overall survival (OS), disease control rate (DCR) and progression free survival (PFS). The results are summarized for both groups below.
Table: 1490P
Median DoT, OS, DCR and PFS
Endpoint (mos) | Overall | Arm 1 | Arm 2 | Arm 3 | ||||
ITT | ≥4 wks | ITT | ≥4 wks | ITT | ≥4 wks | ITT | ≥4 wks | |
DoT | 4.1 | 4.7 | 4.3 | 4.7 | 5.4 | 5.4 | 3.0 | 3.5 |
OS | 9.9 | 11.1 | 16.5 | 17.0 | 9.5 | 9.5 | 7.7 | 10.2 |
PFS | 4.1 | 5.2 | 4.0 | 4.0 | 7.7 | 7.7 | 5.5 | 5.8 |
DCR % | 68.8 | 84.6 | 57.1 | 80.0 | 100.0 | 100.0 | 66.7 | 80.0 |
Conclusions
LW-02 CI alone or combined with chemo- or immunotherapy appears safe with clear anticancer efficacy signals in treating advanced NSCLC. These results, when compared with data from existing therapies, warrant further investigation.
Clinical trial identification
NCT04690686.
Editorial acknowledgement
Legal entity responsible for the study
Immunicom Inc.
Funding
Immunicom Inc.
Disclosure
M. Bozkurt, D. Gökhan, M. Teomete: Financial Interests, Institutional, Principal Investigator: Immunicom Inc.. C. Turam: Financial Interests, Institutional, Coordinating PI: Immunicom Inc.. L. Florin: Financial Interests, Institutional, Member of Board of Directors: Immunicom. A. Ostrowski: Financial Interests, Institutional, Officer, Employee: Immunicom. R. Segal, V. Manax: Financial Interests, Institutional, Member of Board of Directors: Immunicom.
Resources from the same session
1535P - Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the oesophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase II IKF-S627/RAMOS trial of the AIO
Presenter: Magdalena Scheck
Session: Poster session 21
1536P - HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+ advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome
Presenter: Joshua Tobias
Session: Poster session 21
1537P - A phase I study of pevonedistat plus capeOX in patients with advanced gastric cancer refractory to platinum (NCCH-1811)
Presenter: Daisuke Takahari
Session: Poster session 21
1540P - Tislelizumab combined with neoadjuvant chemoradiotherapy for resectable locally advanced oesophageal squamous cell carcinoma: A prospective, phase II clinical study
Presenter: Yi Zhang
Session: Poster session 21
1541P - Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC)
Presenter: Yinjun Dong
Session: Poster session 21
1542P - Updated results of a phase II clinical trial: Paclitaxel and carboplatin plus PD-1 blockades combined with anlotinib as first-line treatment for advanced oesophageal cancer
Presenter: Mingfang Xu
Session: Poster session 21